A venture capital platform specialized in life sciences and medical technology manages multiple funds with total assets under management of approximately $1.5B. The firm has been operating since 2014 and is managed by a professional team with diverse and deep industry experience. To date, the firm has completed more than 90 investments in high-growth-potential companies. Typical allocation sizes for their RMB funds range from RMB 30M to RMB 150M, with the ability to invest up to RMB 200M. For the USD fund, typical investments range from $5-10M, with the ability to invest up to $20M.
The firm is open to investing globally across the broader biomedical sector, including medtech and biotech or therapeutics. The firm focuses on technology-driven, innovative platforms and products that demonstrate clear differentiation and meaningful value creation for patients and the healthcare system overall. Within biotech and therapeutics, the firm prefers companies at the angel or venture stages, particularly those addressing significant unmet clinical needs.
From a company perspective, the firm prefers opportunities that are technology-driven, commercially viable, and capable of solving real-world healthcare problems.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment